“REPLACE Trial of Riociguat for Pulmonary Arterial Hypertension 5th September 2017

Dr Robin Condliffe and the Royal Hallamshire Clinical Research Facility are starting a trial of Riociguat, a drug for people with Pulmonary Arterial Hypertension (PAH). The trial is sponsored by Bayer PLC. Current PAH treatments include phosphodiesterase-5 inhibitors (PDE-5i) which relaxes the blood vessels, thus increasing blood flow to the lungs and lowering blood pressure.

The purpose of this study is to measure the effectiveness of Riociguat as replacement of PDE-5i. It is hoped that people who have not had very successful PDE-5i treatment will show improvement with Riociguat which works via a different molecular mechanism.